Doctor profile · Federal record

Dr. Matthew Cassell, M.D.

Hematology & Oncology Physician (CMS: Hematology/Oncology) · Specialist · Meridian, MS

  • NPI 1427269331
  • Accepts Medicare
  • MIPS 98.6 / 100 · 2023
  • 20 yrs in practice
  • Male
  • Group practice
  • No sanctions

Practice & contact

NPPES Updated May 11, 2026
Primary practice
1704 23Rd Ave, Second Floor
Meridian, MS 393013103
(601) 482-1555
fax (601) 696-4608

Credentials & registration

NPPES · NUCC
NPI registered
May 2007 — 19 yrs on file
Profile last updated
October 15, 2024
Year of graduation
2006 — 20 yrs since
Specialty taxonomy
207RH0003X — NUCC code
State license (1)
Mississippi #20329
Medicaid
MS #009300810

Federal sanctions & exclusions

OIG LEIE Updated May 11, 2026

No sanctions, exclusions or revocations on file

Checked against OIG LEIE on NPI 1427269331. Last verified May 11, 2026.

Medicare procedures · 2023

Top services delivered

CMS Provider Utilization
Total services
84,741
Distinct HCPCS
10
Medicare allowed
$1,629,073
HCPCS Description Services Patients Avg allowed
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) 30,090 23 $1
J9271 Injection, pembrolizumab, 1 mg 13,400 12 $54
J0897 Injection, denosumab, 1 mg 13,380 37 $23
J1449 Injection, eflapegrastim-xnst, 0.1 mg 7,392 20 $32
J1100 Injection, dexamethasone sodium phosphate, 1 mg 5,750 65 $0
J2469 Injection, palonosetron hcl, 25 mcg 3,960 52 $1
36415 Insertion of needle into vein for collection of blood sample 1,275 423 $8
80053 Blood test, comprehensive group of blood chemicals 1,117 393 $10
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count 1,108 375 $8
J9190 Injection, fluorouracil, 500 mg 990 15 $2

In context: peer comparison

Among 2 peers in Meridian Hematology & Oncology Physician, average services per provider: 1,643. This provider delivers 52× the peer median.

Open Payments

Industry payments received

CMS Open Payments
All-time total
$4,817
Transactions
120
Manufacturers
15
Payer (manufacturer) Industry Txns Amount
Novartis Pharmaceuticals Corporation 26 $1,463.24
Janssen Biotech, INC. 12 $353.58
AstraZeneca Pharmaceuticals Lp 11 $315.18
Incyte Corporation 8 $228.03
Merck Sharp & Dohme LLC 10 $224.32
Genzyme Corporation 4 $198.25
E.R. Squibb & Sons, L.L.C. 13 $185.43
Pfizer INC. 7 $141.65
Aveo Pharmaceuticals, INC. 2 $118.10
Celgene Corporation 5 $110.56
Gilead Sciences, INC. 4 $108.66
Genentech USA, INC. 5 $98.02
Lilly USA, LLC 4 $89.47
Astellas Pharma US INC 4 $87.21
GlaxoSmithKline, LLC. 5 $85.31

By nature of payment

Food and Beverage
$3,554
Long Term Medical Supply or Device Loan
$1,164
Education
$100

Medicare Part D · 2023

Top prescriptions

CMS Part D Prescriber
Total claims
591
Patients
138
Total drug cost
$1,625,580
Drug Type Claims Patients Total cost
Letrozole Generic 108 35 $2,542
Ondansetron Hcl Generic 69 37 $792
Tramadol Hcl Generic 67 12 $482
Tamoxifen Citrate Generic 59 19 $1,566
Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen) Brand 42 20 $1,410
Oxycodone-Acetaminophen (Oxycodone Hcl/Acetaminophen) Brand 42 0 $1,381
Pomalyst (Pomalidomide) Brand 32 0 $595,283
Prednisone Generic 31 15 $97
Revlimid (Lenalidomide) Brand 25 0 $457,565
Imbruvica (Ibrutinib) Brand 24 0 $399,548

Hospital affiliations

CMS Hospital Compare

Frequently asked questions

Auto-generated from federal data
What is Dr. Matthew Cassell's medical specialty?
Dr. Matthew Cassell practices Hematology & Oncology Physician in Meridian, MS.
Where does Dr. Matthew Cassell practice?
Dr. Matthew Cassell practices at 1704 23Rd Ave, Meridian, MS 393013103. Office phone: 6014821555.
What is Dr. Matthew Cassell's NPI?
Dr. Matthew Cassell's National Provider Identifier (NPI) is 1427269331, issued by NPPES.
Does Dr. Matthew Cassell accept Medicare assignment?
Yes. Dr. Matthew Cassell accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Matthew Cassell commonly perform?
Top Medicare-reported procedures in 2023: Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS Q0138); Injection, pembrolizumab, 1 mg (HCPCS J9271); Injection, denosumab, 1 mg (HCPCS J0897). Source: CMS Medicare Physician & Other Practitioners file.